CIK 0001690585
- Non-accelerated filer
- Smaller reporting company
Dianthus Therapeutics, Inc. /DE/
Sign in to watch- Ticker
- DNTH
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 929-999-4055
- Business address
- 7 TIMES SQUARE, 43RD FLOOR, NEW YORK, NY, 10036
- Former names
- Magenta Therapeutics, Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $15,717,056
- in 3 filings, $15.7M under 10b5-1 plans
Net −$15,717,056. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −43,505 | $80.69 | $3.5M | 79,413 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −65,517 | $81.74 | $5.4M | 13,896 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −12,796 | $82.60 | $1.1M | 1,100 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −200 | $83.38 | $17K | 900 |
| 2026-03-12 | Garcia Marino CEO AND PRESIDENT | Sale 10b5-1 | −900 | $85.53 | $77K | 0 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −15,852 | $80.71 | $1.3M | 27,830 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −23,465 | $81.75 | $1.9M | 4,365 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −3,865 | $82.66 | $319K | 500 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −200 | $83.38 | $17K | 300 |
| 2026-03-12 | CARR EDWARD CHIEF ACCOUNTING OFFICER | Sale 10b5-1 | −300 | $85.53 | $26K | 0 |
| 2025-12-04 | Savitz Ryan CFO & CBO | Sale 10b5-1 | −20,000 | $45.18 | $904K | 0 |
| 2025-11-14 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −109,031 | $38.14 | $4.2M | 4,000 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −26,166 | $35.80 | $937K | 65,341 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −42,765 | $37.04 | $1.6M | 22,576 |
| 2025-11-13 | Randhawa Simrat EVP, Head of R&D | Sale 10b5-1 | −18,576 | $37.72 | $701K | 4,000 |
| 2025-09-09 | Savitz Ryan CFO & CBO | Sale 10b5-1 | −20,000 | $35.00 | $700K | 0 |
| 2023-02-08 | Third Rock Ventures IV, L.P. 10% owner | Sale | −1,500,000 | $0.82 | $1.2M | 3,058,204 |
| 2023-02-07 | Third Rock Ventures IV, L.P. 10% owner | Sale | −2,200,000 | $0.83 | $1.8M | 4,558,204 |
| 2021-09-16 | Stants Kristen Chief People Officer | Sale | −5,736 | $6.73 | $39K | 14,264 |
| 2021-09-16 | Mahoney Stephen F. | Sale | −5,736 | $6.73 | $39K | 14,264 |
Page 4 of 6 · 119 trades